vatalanib (PTK 787)

May 23, 2008

vatalanib (PTK 787)
Novartis Pharmaceuticals (NVS - East Hanover, NJ)

Current research in glioblastoma multiforme:

Notes: "Combination of imatinib, hydroxyurea and vatalanib is safe and well tolerated with an encouraging rate of radiographic response." (ASCO 2008. Abstract #2057)

OncologyWatch: Posts about free-access articles on aspects of oncology theory, practice and policy (about the blogger).This blog is not a source for medical advice.

Technorati tags:
oncology cancer pharmaceutical industry glioblastoma multiforme

Comments and Links Welcome!

Comments »

The URI to TrackBack this entry is: http://oncologywatch.blogsome.com/2008/05/23/vatalanib-ptk-787/trackback/

No comments yet.

RSS feed for comments on this post.

Leave a comment

Line and paragraph breaks automatic, e-mail address never displayed, HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>



Anti-spam measure: please retype the above text into the box provided.

Get free blog up and running in minutes with Blogsome | Theme designs available here